BioSenic on its way
BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease
December 06, 2023 01:00 ET | BioSenic
PRESS RELEASE – INSIDE INFORMATION         Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment...
BioSenic progresse p
BioSenic progresse pour trouver les fonds nécessaires à la réalisation de son essai clinique clé sur la maladie chronique du greffon contre l'hôte
December 06, 2023 01:00 ET | BioSenic
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIÉE Biosenic signe un protocole d’accord avec SPRIM Global Investments (fonds TrialCap) pour un financement par emprunt de 8 millions d'USD et une...
BioSenic performs fu
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD
September 27, 2023 01:00 ET | BioSenic
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD New post-hoc analysis...
BioSenic poursuit l'
BioSenic poursuit l'analyse des données de son essai clinique de phase 2, ce qui lui permet de définir un schéma d'administration optimal pour son prochain essai de phase avancée sur l'arsenic trioxide dans le traitement de la cGvHD
September 27, 2023 01:00 ET | BioSenic
INFORMATION PRIVILEGIÉE La nouvelle analyse post-hoc est en faveur d’une répétition du cycle d'administration pour le prochain essai de phase 3 de BioSenic utilisant l'arsenic trioxide (ATO) oral...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. to Present at the LD Micro Main Event XVI
September 21, 2023 13:30 ET | Cingulate Inc.
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
OptimiTM-03.jpg
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
September 14, 2023 14:59 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Pricing of $4.0 Million Public Offering
September 11, 2023 09:22 ET | Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) --  Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, FIRM Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
August 19, 2023 17:52 ET | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023 16:15 ET | Cingulate Inc.
Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway ...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
July 27, 2023 11:27 ET | The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rain...